Danske Bank A S Invests $108.76 Million in Danaher Corporation $DHR

Key Points

• Danske Bank acquired 151,052 Danaher shares during the second quarter, worth approximately $108.76 million. Institutional investors own 79.05% of Danaher’s stock.
• Danaher reported quarterly earnings of $1.94 per share, exceeding estimates of $1.85, while revenue rose 5.5% year over year to $6.26 billion.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $228.91, versus the stock’s reported price of $199.62.

Danske Bank A S acquired a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 151,052 shares of the conglomerate's stock, valued at approximately $108,763,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Main Street Group LTD bought a new stake in Danaher in the 1st quarter valued at $25,000. N.E.W. Advisory Services LLC bought a new position in shares of Danaher during the 2nd quarter worth about $25,000. JPL Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter valued at about $25,000. Elevated Capital Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter valued at about $26,000. Finally, WFA of San Diego LLC bought a new stake in Danaher in the second quarter valued at about $26,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 1.5%

NYSE DHR opened at $199.62 on Wednesday. The stock's 50 day simple moving average is $193.74 and its 200 day simple moving average is $192.50. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The firm has a market cap of $140.33 billion, a PE ratio of 35.46, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to analysts' expectations of $6.12 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The business's revenue for the quarter was up 5.5% on a year-over-year basis. As a group, sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on DHR. Royal Bank Of Canada raised their price target on shares of Danaher from $200.00 to $215.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 22nd. Jefferies Financial Group reissued a "buy" rating and issued a $245.00 target price on shares of Danaher in a report on Tuesday, April 21st. UBS Group cut their target price on Danaher from $270.00 to $250.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. DZ Bank assumed coverage on Danaher in a research report on Wednesday, June 3rd. They issued a "buy" rating and a $210.00 price target on the stock. Finally, Argus dropped their price objective on Danaher from $265.00 to $230.00 and set a "buy" rating for the company in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.91.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source